U.S. Markets open in 4 hrs 18 mins

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
56.51-1.44 (-2.48%)
At close: 4:00PM EDT
People also watch
SAGEXLRNRDUSAGIOPTLA

Ultragenyx Pharmaceutical Inc.

60 Leveroni Court
Novato, CA 94949
United States
415-483-8800
http://www.ultragenyx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees376

Key Executives

NameTitlePayExercisedAge
Dr. Emil D. Kakkis M.D., Ph.D.Chief Exec. Officer, Pres and Director945.9kN/A57
Ms. Shalini SharpChief Financial Officer and Exec. VP658.44k2.9M42
Ms. Karah Herdman ParschauerExec. VP and Gen. Counsel320.96kN/A39
Mr. John Richard Pinion IIChief Quality Operations Officer and Exec. VP of Analytical Sciences & Research601.46kN/A51
Dr. Jayson Donald Alexander Dallas M.D.Chief Commercial Officer and Exec. VP697.26kN/A49
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid, which is in Phase III extension study to treat GNE myopathy. It has collaboration and license agreements with Arcturus Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; Nobelpharma Co., Ltd.; Alcami Corporation; HIBM Research Group; and St. Jude Children’s Research Hospital. The company was founded in 2010 and is headquartered in Novato, California.

Corporate Governance

Ultragenyx Pharmaceutical Inc.’s ISS Governance QualityScore as of August 1, 2017 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.